• Diabetic cases controlled with low carbohydrate diet (LCD) and GLP-1 receptor agonist (GLP-1 RA)
    • Shirakawa, M
    • Kanamoto, Y
    • Nagaoka, H
    • Honda, H
    • Bando, Hiroshi
  • © 2019 Shirakawa M, Kanamoto Y, Nagaoka H, et al., This is an open access article distributed under the Creative Commons Attribution License(, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • Other Low Carbohydrate Diet (LCD)
  • Other GLP-1 Receptor Agonist (GLP-1 RA)
  • Other Dulaglutide
  • Other Type 2 Diabetes Mellitus (T2DM)
  • Other Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
  • Other Intestine Secretion Insulin (INCRETIN)
  • Other Recent treatment for type 2 diabetes mellitus (T2DM) has included glucagon-like peptide-1 receptor agonist (GLP-1 RA), indicating clinical efficacy for better glucose variability. Subjects were seven patients with T2DM associated with the obese tendency. Their average age was 63.8 ± 21.7 years old (5 males, 2 females) who received a new administration of GLP-1 RA (Mean ± standard deviation). For GLP-1 RA, dulaglutide (TRULICITY R, single-dose pen) was administered by subcutaneous injection 0.75 mg once a week. Basal data at 0 month revealed that body weight 76.0 ± 11.6 kg, body mass index (BMI) 29.2 ± 11.6, blood C-peptide immunoreactivity (CPR) 2.68 ± 0.49 ng/mL, respectively. After the intervention of dulaglutide, decreased value of BMI for 3 and 6-9 months was 0.78 ± 0.45 and 1.16 ± 0.85, and HbA1c for 3 and 6-9 months was 1.60 ± 1.52% and 2.01 ± 1.44%, respectively. Though these cases have various complications besides T2DM, they showed clinical effects of weight reduction and lowering blood glucose. Diabetic treatment for current cases would suggest that GLP-1 RA would be effective in various situations such as a super-aged patient, medical practice in the remote area, family care and visiting nursing.
Publisher Asploro
  • eng
Resource Type journal article
Version Type VoR
Identifier URI
    • ISSN 2582-0370
      • Asploro Journal of Biomedical and Clinical Case Reports 2(s1), 38-46
Oaidate 2021-04-07